Reported segment mix · SEC DERA dimensional facts

Theravance Biopharma, Inc. TBPH revenue by segment, product and geography

In its fiscal year ending 2025-12-31, Theravance Biopharma, Inc. reported revenue across 1 business segments; the largest, Single Reportable Segment, was $107M, 100.0% of the filed sum (+66.9% against the prior period in the same filing).

Full financial analysis →Company overview →

Reported segment mix

figures as filed · share of the filed sum · change vs the prior period in the same filing

Fiscal year ending 2025-12-3110-K filed 2026-03-23prior period 2024-12-31 from the same filingView filing

By business segment

Revenue

Single Reportable Segment$107M
100.0%
+66.9% yoy

Members sum to the consolidated $107M for this period.

Operating income

Single Reportable Segment-$3.6M
100.0%
-92.3% yoy

Members sum to the consolidated -$3.6M for this period.

By product or service

Revenue

Collaborative Arrangement Revenue$75M
share n/a
+16.4% yoy
Licensing And Milestone$32.5M
share n/a
no prior
Milestone$25M
share n/a
no prior
License$7.5M
share n/a
no prior

member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.

By geography

Revenue

United States$75M
69.8%
+16.4% yoy
Europe$32.5M
30.2%
no prior

Members sum to the consolidated $107M for this period.

Latest quarter

Quarter ending 2026-03-3110-Q filed 2026-05-07prior period 2025-03-31 from the same filingView filing

Single Reportable Segment$17.7M
100.0%
+15.0% yoy

Change is against the same quarter a year earlier, as reported in the same 10-Q.

Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.

About these figures

Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.

Descriptive and educational; not investment advice. Methodology and data lineage.